Diamyd Medical AB (publ)
Climate Impact & Sustainability Data (2002-09-01 to 2003-08-31)
Reporting Period: 2002-09-01 to 2003-08-31
Environmental Metrics
Climate Goals & Targets
Medium-term Goals:
- Continue to build value into Diamyd Medical.
Short-term Goals:
- Identify a partner for further commercialization of Diamyd™.
- Increase awareness of autoimmune diabetes, including LADA, among the medical community.
Environmental Challenges
- Risks concerning efficacy of Diamyd™ in humans.
- Risks concerning the suitability of Diamyd™ for human administration (toxicity, disease induction).
- Production risks (timely production, sufficient quality for clinical trials, scalability of manufacturing).
- Patent risks (sufficiency and adequacy of licensed intellectual property rights).
- Competition from other diabetes prevention strategies.
- Competition in diabetes-related diagnostic kits.
- Partnership risks (finding a suitable partner, building effective distribution structure, securing beneficial partnership agreements).
- Financial risks (securing adequate financial resources).
- Agreement risks (concluding sufficiently good agreements, protecting against breaches of contract).
- Currency risks (exchange rate fluctuations affecting development plans).
Mitigation Strategies
- Outsourcing strategy for research and development, carefully monitoring outsourced tasks.
- Key personnel insurance (SEK 5 million for CEO and Director of R&D).
- Seeking collaboration with a major pharmaceutical company for further commercialization of Diamyd™.
- Continuous monitoring of research and development of other applications for GAD.
- Major agreements reviewed by the Company’s legal advisor.
- Minimizing currency exposure by balancing income and expenses (no foreign currency hedging).